File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Risk factors for avascular necrosis of bone in patients with systemic lupus erythematosus: Is there a role for antiphospholipid antibodies?

TitleRisk factors for avascular necrosis of bone in patients with systemic lupus erythematosus: Is there a role for antiphospholipid antibodies?
Authors
Issue Date2000
PublisherB M J Publishing Group. The Journal's web site is located at http://ard.bmjjournals.com/
Citation
Annals Of The Rheumatic Diseases, 2000, v. 59 n. 6, p. 462-467 How to Cite?
AbstractBackground - Avascular necrosis of bone (AVN) is a well known complication in patients with systemic lupus erythematosus (SLE). Objective - To investigate the role of antiphospholipid antibody status (IgM and IgG anticardiolipin antibodies and lupus anticoagulant) with adjustment for corticosteroid use as risk factors for the development of AVN. Methods - A cohort of 265 patients receiving long term follow up in our SLE clinic from 1978 to 1998 was analysed. Patients with AVN complications were detected and then matched for age, sex, ethnicity, duration of disease, and organ disease with two other patients with SEE. A further 31 patients were chosen at random for the analysis. Results - Eleven patients had AVN, giving a point prevalence of 4%. There were no significant differences demonstrable in the presence of individual antiphospholipid antibodies (aPL) or their combination between the group with AVN or the two control groups. Conclusion - Incorporating an adjustment for corticosteroid use we were unable to show a link between the presence of aPL and the development of AVN in patients with SLE.
Persistent Identifierhttp://hdl.handle.net/10722/162429
ISSN
2015 Impact Factor: 12.384
2015 SCImago Journal Rankings: 4.537
ISI Accession Number ID
References

 

DC FieldValueLanguage
dc.contributor.authorMok, MYen_US
dc.contributor.authorFarewell, VTen_US
dc.contributor.authorIsenberg, DAen_US
dc.date.accessioned2012-09-05T05:19:50Z-
dc.date.available2012-09-05T05:19:50Z-
dc.date.issued2000en_US
dc.identifier.citationAnnals Of The Rheumatic Diseases, 2000, v. 59 n. 6, p. 462-467en_US
dc.identifier.issn0003-4967en_US
dc.identifier.urihttp://hdl.handle.net/10722/162429-
dc.description.abstractBackground - Avascular necrosis of bone (AVN) is a well known complication in patients with systemic lupus erythematosus (SLE). Objective - To investigate the role of antiphospholipid antibody status (IgM and IgG anticardiolipin antibodies and lupus anticoagulant) with adjustment for corticosteroid use as risk factors for the development of AVN. Methods - A cohort of 265 patients receiving long term follow up in our SLE clinic from 1978 to 1998 was analysed. Patients with AVN complications were detected and then matched for age, sex, ethnicity, duration of disease, and organ disease with two other patients with SEE. A further 31 patients were chosen at random for the analysis. Results - Eleven patients had AVN, giving a point prevalence of 4%. There were no significant differences demonstrable in the presence of individual antiphospholipid antibodies (aPL) or their combination between the group with AVN or the two control groups. Conclusion - Incorporating an adjustment for corticosteroid use we were unable to show a link between the presence of aPL and the development of AVN in patients with SLE.en_US
dc.languageengen_US
dc.publisherB M J Publishing Group. The Journal's web site is located at http://ard.bmjjournals.com/en_US
dc.relation.ispartofAnnals of the Rheumatic Diseasesen_US
dc.subject.meshAdolescenten_US
dc.subject.meshAdulten_US
dc.subject.meshAntibodies, Anticardiolipin - Blooden_US
dc.subject.meshAntibodies, Antiphospholipid - Blooden_US
dc.subject.meshBiological Markers - Blooden_US
dc.subject.meshCase-Control Studiesen_US
dc.subject.meshFemaleen_US
dc.subject.meshFollow-Up Studiesen_US
dc.subject.meshHumansen_US
dc.subject.meshImmunoglobulin G - Analysisen_US
dc.subject.meshImmunoglobulin M - Analysisen_US
dc.subject.meshLupus Coagulation Inhibitor - Blooden_US
dc.subject.meshLupus Erythematosus, Systemic - Complications - Immunologyen_US
dc.subject.meshMiddle Ageden_US
dc.subject.meshOsteonecrosis - Etiology - Immunologyen_US
dc.subject.meshRisk Factorsen_US
dc.titleRisk factors for avascular necrosis of bone in patients with systemic lupus erythematosus: Is there a role for antiphospholipid antibodies?en_US
dc.typeArticleen_US
dc.identifier.emailMok, MY:temy@hkucc.hku.hken_US
dc.identifier.authorityMok, MY=rp00490en_US
dc.description.naturelink_to_subscribed_fulltexten_US
dc.identifier.doi10.1136/ard.59.6.462en_US
dc.identifier.pmid10834864en_US
dc.identifier.scopuseid_2-s2.0-0034121183en_US
dc.relation.referenceshttp://www.scopus.com/mlt/select.url?eid=2-s2.0-0034121183&selection=ref&src=s&origin=recordpageen_US
dc.identifier.volume59en_US
dc.identifier.issue6en_US
dc.identifier.spage462en_US
dc.identifier.epage467en_US
dc.identifier.isiWOS:000087533300014-
dc.publisher.placeUnited Kingdomen_US
dc.identifier.scopusauthoridMok, MY=7006024184en_US
dc.identifier.scopusauthoridFarewell, VT=7005718187en_US
dc.identifier.scopusauthoridIsenberg, DA=36051280800en_US

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats